Camizestrant

Camizestrant
Clinical data
Other names	AZD9833
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine;
CAS Number	2222844-89-3;
PubChem CID	134453496;
IUPHAR/BPS	12716;
DrugBank	DB19218;
ChemSpider	103820855;
UNII	JUP57A8EPZ;
KEGG	D12049;
ChEMBL	ChEMBL4650365;
Chemical and physical data
Formula	C24H28F4N6
Molar mass	476.524 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF;
	InChI InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1; Key:WDHOIABIERMLGY-CMJOXMDJSA-N;

Camizestrant is an investigational new drug that is being evaluated to treat breast cancer.^[1] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD).^[2]

References

^ "Camizestrant - AstraZeneca". AdisInsight. Springer Nature Switzerland AG.
^ Scott JS, Moss TA, Balazs A, Barlaam B, Breed J, Carbajo RJ, et al. (December 2020). "Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist". Journal of Medicinal Chemistry. 63 (23): 14530–14559. doi:10.1021/acs.jmedchem.0c01163. PMID 32910656.